New study reviews how chinese patients actually use lung cancer drug lorlatinib
NCT ID NCT07556549
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This study looks back at medical records of 50 Chinese adults with advanced ALK-positive non-small cell lung cancer who received lorlatinib as their first treatment. Researchers want to learn about patient characteristics, such as age and smoking history, and how the drug is used in real-world clinics. The goal is to gather information, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lorlatinib
- What this could lead to
- If successful, this study could help doctors understand how lorlatinib is used in everyday practice in China, potentially guiding better treatment decisions for ALK-positive lung cancer patients.
- What could go wrong
- This is a retrospective chart review, not a controlled trial, so it cannot prove cause and effect. Results may be limited by incomplete records or small sample size (50 patients).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER ALK-POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Beijing, China